View AMCP comments to the CMS’s Advance Notice of Methodological Changes for Calendar Year (CY) 2026 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies
View AMCP comments to the CMS’s Draft CY 2026 Part D Redesign Program Instructions.
View AMCP comments to the FDA on considerations in demonstrating biosimilar interchangeability with a biologic reference product.
AMCP webinar that reviewed the provisions contained in the proposed Contract Year 2021 and 2022 Medicare Advantage and Part D rule that was released by the Centers for Medicare and Medicaid Services (CMS) on February 5, 2020.
AMCP webinar that reviewed the provisions contained in the proposed Contract Year 2021 and 2022 Medicare Advantage and Part D rule that was released by the Centers for Medicare and Medicaid Services (CMS) on February 5, 2020.
AMCP webinar that reviewed the provisions contained in the proposed Contract Year 2021 and 2022 Medicare Advantage and Part D rule that was released by the Centers for Medicare and Medicaid Services (CMS) on February 5, 2020.
AMCP webinar that reviewed the provisions contained in the draft 2020 CMS Medicare Part D Call Letter that was released by the Centers for Medicare and Medicaid Services (CMS) on January 30, 2019.
AMCP webinar that reviewed the provisions contained in the draft 2020 CMS Medicare Part D Call Letter that was released by the Centers for Medicare and Medicaid Services (CMS) on January 30, 2019.
AMCP comments on legislation that would increase competition and decrease patients' drug costs.
AMCP letter to Chairman Grassley and Ranking Member Feinstein of the Senate Judiciary Committee
AMCP webinar that reviewed the FDA Reauthorization Act of 2017 (FDARA) which authorizes user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.
AMCP webinar that reviewed the FDA Reauthorization Act of 2017 (FDARA) which authorizes user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.
